Suppr超能文献

RNA干扰的应用:基于小干扰RNA的体内策略的现状与前景

Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.

作者信息

Aigner Achim

机构信息

Department Pharmacology and Toxicology, School of Medicine, Philipps-University Marburg, Karl-von-Frisch-Strasse 1, 35033, Marburg, Germany.

出版信息

Appl Microbiol Biotechnol. 2007 Aug;76(1):9-21. doi: 10.1007/s00253-007-0984-y. Epub 2007 Apr 25.

Abstract

Within the recent years, RNA interference (RNAi) has become an almost-standard method for in vitro knockdown of any target gene of interest. Now, one major focus is to further explore its potential in vivo, including the development of novel therapeutic strategies. From the mechanism, it becomes clear that small interfering RNAs (siRNAs) play a pivotal role in triggering RNAi. Thus, the efficient delivery of target gene-specific siRNAs is one major challenge in the establishment of therapeutic RNAi. Numerous studies, based on different modes of administration and various siRNA formulations and/or modifications, have already accumulated promising results. This applies to various animal models covering viral infections, cancer and multiple other diseases. Continuing efforts will lead to the development of efficient and "double-specific" drugs, comprising of siRNAs with high target gene specificity and of nanoparticles enhancing siRNA delivery and target organ specificity.

摘要

近年来,RNA干扰(RNAi)已成为体外敲低任何感兴趣的靶基因的一种几乎标准的方法。现在,一个主要的重点是进一步探索其在体内的潜力,包括开发新的治疗策略。从机制上看,很明显小干扰RNA(siRNA)在触发RNAi中起关键作用。因此,靶基因特异性siRNA的有效递送是建立治疗性RNAi的一个主要挑战。基于不同给药方式以及各种siRNA制剂和/或修饰的大量研究已经积累了有前景的结果。这适用于涵盖病毒感染、癌症和多种其他疾病的各种动物模型。持续的努力将导致开发高效且“双特异性”的药物,其由具有高靶基因特异性的siRNA和增强siRNA递送及靶器官特异性的纳米颗粒组成。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fcc/7079960/756d91178c4c/253_2007_984_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验